Literature DB >> 12057170

Gastrointestinal stromal tumors.

E S Casper1.   

Abstract

The nonepithelial, nonlymphoid tumors of the gastrointestinal tract are heterogeneous in terms of clinical presentation, behavior, pathology, and genetic features. Concepts regarding these tumors have changed rapidly over the past decade as nomenclature has evolved. Many of these tumors have no muscle differentiation, and designations such as leiomyoma or leiomyosarcoma are inappropriate for many of these neoplasms. With an improved understanding of the biology of these tumors, gastrointestinal stromal tumor (GIST) is used as a specific term for tumors of the gastrointestinal tract that lack markers of myogenic differentiation, but stain positive for vimentin, and express CD34 and CD117, the product of the c-kit oncogene. Both benign and malignant types are recognized. In addition to myogenic tumors and GIST, gastrointestinal autonomic nerve tumors (GANT) are also recognized. Complete en bloc surgical resection, when possible, is the cornerstone of therapy. Metastasis tends to occur to the liver and within the peritoneal cavity, especially in patients whose tumors have ruptured spontaneously or been violated by the surgeon. Incomplete surgical resection and metastatic disease indicate a dismal prognosis in the majority of patients. Recurrent or metastatic disease is often resected, but this has an uncertain impact on outcome. Operation may palliate patients with intestinal obstruction or other symptoms. For patients with unresectable disease, the results with systemic chemotherapy have been dismal. Treatment with doxorubicin/ifosfamide combinations is of dubious value. Hepatic arterial embolization, with and without intra-arterial chemotherapy, results in regression of liver metastases in selected patients. Regression has also been seen using intrahepatic arterial infusion of doxorubicin without embolization. The impact of such treatment on outcome, however, is poorly studied. Aggressive surgical resection of peritoneal metastases with intraperitoneal chemotherapy has been advocated, but requires formal study in large trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12057170     DOI: 10.1007/s11864-000-0039-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  28 in total

1.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

Authors:  M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

Authors:  M Zalupski; B Metch; S Balcerzak; W S Fletcher; R Chapman; J D Bonnet; G R Weiss; J Ryan; R S Benjamin; L H Baker
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

3.  Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment.

Authors:  B Berthet; T A Sugarbaker; D Chang; P H Sugarbaker
Journal:  Eur J Cancer       Date:  1999-03       Impact factor: 9.162

4.  CT evaluation of small bowel neoplasms: spectrum of disease.

Authors:  J A Buckley; E K Fishman
Journal:  Radiographics       Date:  1998 Mar-Apr       Impact factor: 5.333

5.  Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas.

Authors:  E H Ng; R E Pollock; M M Romsdahl
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

6.  Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine.

Authors:  G M Mavligit; A A Zukwiski; L M Ellis; V P Chuang; S Wallace
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

7.  Gastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases.

Authors:  G Y Lauwers; R A Erlandson; E S Casper; M F Brennan; J M Woodruff
Journal:  Am J Surg Pathol       Date:  1993-09       Impact factor: 6.394

8.  Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry.

Authors:  R A Erlandson; D S Klimstra; J M Woodruff
Journal:  Ultrastruct Pathol       Date:  1996 Jul-Aug       Impact factor: 1.094

Review 9.  Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know.

Authors:  H D Appelman
Journal:  Am J Surg Pathol       Date:  1986       Impact factor: 6.394

Review 10.  Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease).

Authors:  C E Fuller; G T Williams
Journal:  Histopathology       Date:  1991-07       Impact factor: 5.087

View more
  10 in total

1.  Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib.

Authors:  Karen E Mulder; Merrill J Egorin; Michael B Sawyer
Journal:  Invest New Drugs       Date:  2011-11-25       Impact factor: 3.850

Review 2.  FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.

Authors:  Philipp Malle; Manfred Sorschag; Hans-Jürgen Gallowitsch
Journal:  Wien Med Wochenschr       Date:  2012-08-14

3.  Gastrointestinal stromal tumors: experience in 49 patients.

Authors:  Eva Artigau Nieto; Alexis Luna Aufroy; Elsa Dalmau Pórtulas; Pere Rebasa Cladera; Ruth Orellana Fernández; Ana Darnell Martín; Salvador Navarro Soto; Carles Pericay Pijaume
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

4.  Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors.

Authors:  Shee-Chan Lin; Ming-Jer Huang; Chen-Yuan Zeng; Tzang-In Wang; Zen-Liang Liu; Ray-Kuan Shiay
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

Review 5.  Targeting minimal residual disease: a path to cure?

Authors:  Marlise R Luskin; Mark A Murakami; Scott R Manalis; David M Weinstock
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

6.  [Malignant gastrointestinal stromal tumor (GIST) of the papilla vateri. A rare tumor entity].

Authors:  K Wellmann; G Gohla; H Wenk
Journal:  Chirurg       Date:  2004-02       Impact factor: 0.955

7.  Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.

Authors:  Luis Paz-Ares; Xavier García del Muro; Enrique Grande; Paloma González; M Brosa; Silvia Díaz
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

8.  Metastatic duodenal GIST: role of surgery combined with imatinib mesylate.

Authors:  Kamran Mohiuddin; Saira Nizami; Asma Munir; Breda Memon; Muhammed A Memon
Journal:  Int Semin Surg Oncol       Date:  2007-03-29

Review 9.  Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.

Authors:  Kenji Nakano; Shunji Takahashi
Journal:  Int J Mol Sci       Date:  2018-03-05       Impact factor: 5.923

10.  Large duodenal GIST with massive liver secondaries melting under Imatinib: a case report.

Authors:  S Sankar; M Subramanian; T Arunkumar; N Venu; K Anand
Journal:  Cases J       Date:  2008-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.